ArticleScientific reports2025
A comprehensive kinetic model for ternary complex catalysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A quantitative approach for defining the degradability landscape of protein degraders.Nature communications · 2026Article
- Gaps and paths forward in cancer pharmacology and translational research.Frontiers in pharmacology · 2026Review
- Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods.Journal of chemical information and modeling · 2023Review
- Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence.Journal of the American Chemical Society · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ternary-complex catalysis (TEC) plays a central role in many biological processes and underlies the mechanism of action for a growing class of clinical therapeutics, including growth hormones, interferons, heparin, bispecific antibodies, molecular glues, and PROTACs. Despite its importance, TEC remains conceptually opaque due to the complexity of its multi-body interactions and the lack of a unifying kinetic model. Here, we introduce a general and intuitive kinetic framework for TEC that extends the classic Michaelis–Menten model to ternary systems. By solving for the maximum catalytic rate (Vmax) and revisiting an often-overlooked insight from Michaelis and Menten’s original work – the integration of the velocity equation – we derive equations that are analytically simple yet conceptually powerful. These equations clarify how enzyme concentration, catalytic rate (kcat), and the weakest binding affinity (Kweak) jointly determine the reaction timescale, defined here as the half-life for conversion of the target species to the product under pre-equilibrium conditions. We validate our framework across a wide range of TEC-mediated systems, including heparin-based anticoagulants, PROTAC-mediated protein degradation, and antibody-dependent cell killing. To promote broader accessibility and application, we developed an interactive web-based tool ( https://douglasslab.com/Btmax_kinetics/ ) that allows users to simulate catalytic timescales under real-world conditions using thermodynamic and kinetic datasets. By bridging historical theory with modern therapeutic challenges, this work provides a unifying conceptual lens and practical tools for studying and optimizing TEC-driven biology and drug action.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.